Blood Advances · 2019 · 16 citations · 42 references
EngineeringBioengineeringBiotechnologyHemostasisRegenerative MedicineTissue EngineeringEx Vivo Gene DeliveryVascularization StrategiesBiologic GraftsBlood Vessel Tissue EngineeringFactor Viii ActivationFactor Viii PhysiologyFactor Viii ReplacementRecombinant Activated Factor ViiTissue-engineered Blood VesselsVascularization Of Engineered Tissues
Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient's life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown preliminary successes. However, hurdles remain, including lack of infection specificity and the inability to deliver the full-length version of F8 due to restricted viral cargo sizes. Here, we developed an alternative nonviral ex vivo gene-therapy approach that enables the overexpression of full-length F8 in patients' endothelial cells (ECs). We first generated HA patient-specific induced pluripotent stem cells (HA-iPSCs) from urine epithelial cells and genetically modified them using a piggyBac DNA transposon system to insert multiple copies of full-length F8. We subsequently differentiated the modified HA-iPSCs into competent ECs with high efficiency, and demonstrated that the cells (termed HA-FLF8-iECs) were capable of producing high levels of FVIII. Importantly, following subcutaneous implantation into immunodeficient hemophilic (SCID-f8ko) mice, we demonstrated that HA-FLF8-iECs were able to self-assemble into vascular networks, and that the newly formed microvessels had the capacity to deliver functional FVIII directly into the bloodstream of the mice, effectively correcting the clotting deficiency. Moreover, our implant maintains cellular confinement, which reduces potential safety concerns and allows effective monitoring and reversibility. We envision that this proof-of-concept study could become the basis for a novel autologous ex vivo gene-therapy approach to treat HA.
42
A more efficient method to generate integration-free human iPS cells
Keisuke Okita, Yasuko Matsumura, Yoshiko Sato et al. · Nature Methods · 2011 · 2.1K citations · Full text
Resetting Transcription Factor Control Circuitry toward Ground-State Pluripotency in Human
Yasuhiro Takashima, Ge Guo, Remco Loos et al. · Cell · 2014 · 976 citations · Full text
Generation of human induced pluripotent stem cells from urine samples
Ting Zhou, Christina Benda, Sarah Dunzinger et al. · Nature Protocols · 2012 · 619 citations
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw, Johanna G. van der Bom, Rolf Ljung et al. · New England Journal of Medicine · 2013 · 436 citations · Full text
Medicine, Hematology, Pediatrics +16